Meeting Overview - The shareholders' meeting of GeKowei Co., Ltd. was held on June 13, 2025, in Shanghai, China [1] - A total of 312 ordinary shareholders attended the meeting, representing 1,414,182,058 voting rights, which accounts for 55.0019% of the company's total voting rights [1] Voting Results - All non-cumulative voting proposals were approved with significant majority support from ordinary shareholders, with votes such as 1,412,057,449 in favor (99.8497%) and 2,015,794 against (0.1425) for one of the proposals [1][2] - The voting results for various proposals showed consistent approval rates above 99%, indicating strong shareholder support [2][3] Legal Compliance - The meeting was convened and conducted in accordance with the laws of the Cayman Islands and the company's articles of association, ensuring the legality and validity of the proceedings and resolutions [3]

证券代码：688728 证券简称：格科微 公告编号：2025-020 格科微有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 6 月 13 日 （二） 股东大会召开的地点：中国（上海）自由贸易试验区盛夏路 560 号 2 幢 第 11 层 1101 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 312 | | --- | --- | | 普通股股东人数 | 312 | | 2、出席会议的股东所持有的表决权数量 | 1,414,182,058 | | 普通股股东所持有表决权数量 | 1,414,182,058 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 55.0019 | 注：上述出席会议的股东所持有的表决权数量占公司表决权数量的比例，已剔除截至股权登 ...

大成 DENTONS 大成 is Dentons' Preferred Law Firm in China. dentons.cn 北京大成(上海)律师事务所 关于格科微有限公司(GALAXYCORE INC.) 2024 年年度股东大会的 A.d. is Dentons' Preferred Law Firm in China. 北京大成(上海)律师事务所 www.dentons.cn 上海市世纪大道 100 号环球金融中心 9 层、24 层、25 层(200120) 9th/24th/25th Floor, Shanghai World Financial Center, 100 Century Avenue Shanghai 200120, P. R. China Tel: +86 21 5878 5888 Fax: +86 21 5878 6866 Dentons' Preferred Law Firm in China, 北京大成(上海)律师事务所 法律意见书 关于格科微有限公司(GALAXYCORE INC.) 2024 年年度股东大会的法律意见书 致:格科微有限公司(GALAXYCORE INC ...

Group 1 - The National Semiconductor Chip Index (980017) has shown a slight increase of 0.06% as of June 6, 2025, with notable gains from stocks such as Zhaoyi Innovation (603986) up by 4.75% and Geke Micro (688728) up by 1.45% [1] - The semiconductor ETF (159813) is experiencing mixed trading, with the latest quote at 0.78 yuan, reflecting a 0.26% increase [2] - Over the past nine trading days, there have been net inflows of funds on six days, totaling 108 million yuan, with an average daily net inflow of 12.05 million yuan [2] Group 2 - The "5th China Integrated Circuit Design Innovation Conference and IC Application Ecological Exhibition" (ICDIA) is scheduled for July 11-12, 2025, in Suzhou, focusing on themes such as AI computing, photonic integrated circuits, and 5G/6G semiconductors [3] - Shanghai Securities maintains a bullish outlook on the electronics sector, predicting a comprehensive recovery in the semiconductor industry by 2025, with an optimistic overall development outlook [3] - The semiconductor ETF closely tracks the National Semiconductor Chip Index, reflecting the market performance of listed companies in the semiconductor industry [3] Group 3 - As of May 30, 2025, the top ten weighted stocks in the National Semiconductor Chip Index account for 66.85% of the index, including companies like SMIC (688981) and Cambrian (688256) [4] - The semiconductor ETF has various connection options, including A, C, and I classes [4]

证券代码：688728 证券简称：格科微 格科微有限公司 2024 年年度股东大会会议资料 2025 年 6 月 | 2024 | 年年度股东大会须知 | 1 | | --- | --- | --- | | 2024 | 年年度股东大会会议议程 | 3 | | 听取《2024 | 年度独立董事述职报告》 | 5 | | 2024 | 年年度股东大会会议议案 | 6 | | 议案一：关于 2024 | 年度董事会工作报告的议案 6 | | | 议案二：关于 2024 | 年度财务决算报告的议案 12 | | | 议案三：关于 2024 | 年年度利润分配方案的议案 17 | | | 议案四：关于 2024 | 年年度报告及摘要的议案 19 | | | 议案五：关于聘请公司 | 2025 年度财务审计机构及内控审计机构的议案 20 | | | 议案六：关于 2025 | 年度申请综合授信额度的议案 21 | | | 议案七：关于 2025 | 年度对外担保额度预计的议案 22 | | | 议案八：关于董事 2025 | 年度薪酬方案的议案 25 | | | | 议案九：关于修订公司章程的议案 26 | | 格科微 ...

Core Insights - The global smartphone CMOS image sensor (CIS) shipment is expected to grow by 2% year-on-year in 2024, reaching 4.4 billion units [1][4] - Sony remains the market leader, followed by GalaxyCore and OmniVision [1][4] Group 1: Market Predictions - The average number of cameras per smartphone is projected to decrease from 3.8 in 2023 to 3.7 in 2024 [4] - The increase in CIS shipments is driven by a recovery in end-market demand [4] - The average selling price (ASP) of CIS is expected to rise due to advancements in technologies like LOFIC and multispectral imaging [6] Group 2: Company Performances - Sony's shipment volume has slightly increased due to improved production yields and higher demand for premium smartphones [4] - GalaxyCore's shipment volume has surged by 34% year-on-year, attributed to its cost efficiency and transition to a light wafer fab model [4][5] - OmniVision anticipates a 14% year-on-year growth in shipments, supported by the success of its 50MP image sensor [5] Group 3: Market Dynamics - SK Hynix plans to exit the CIS business by March 2025, potentially creating new growth opportunities for Chinese suppliers like GalaxyCore and OmniVision [5] - Geopolitical tensions and macroeconomic uncertainties are expected to pose challenges to the global smartphone market, leading to a slight decline in CIS shipments in 2025 [6]

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 证券代码：688728 证券简称：格科微 公告编号：2025-019 格科微有限公司 关于召开2024年年度股东大会的通知 （一） 股东大会类型和届次 2024年年度股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 股东大会召开日期：2025年6月13日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 召开日期时间：2025 年 6 月 13 日 14 点 00 分 召开地点：中国（上海）自由贸易试验区盛夏路 560 号 2 幢第 11 层 1101 会 议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 13 日 至2025 年 6 月 13 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为 ...

特此公告。 格科微有限公司董事会 2025年5月23日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 格科微有限公司（以下简称"公司"）全资子公司格科微电子（上海）有限公 司（以下简称"格科微上海"）作为有限合伙人以自有资金人民币5,000.00万元认 购上海华科致芯创业投资合伙企业（有限合伙）（以下简称"目标基金"或"合伙企 业"）财产份额。该轮募集完成后，合伙企业的认缴出资总额为人民币30,900.00 万元，格科微上海在合伙企业的认缴出资比例为16.18%，具体详见公司于2025 年4月2日在上海证券交易所网站（www.sse.com.cn）披露的《格科微有限公司关 于对外投资暨关联交易的公告》（公告编号：2025-007）。 近日，公司收到基金管理人上海华登高科私募基金管理有限公司通知，目标 基金已在中国证券投资基金业协会完成备案手续并取得私募投资基金备案证明， 备案信息如下： 公司将根据目标基金的后续进展情况，按照有关法律法规的规定和要求，及 时履行信息披露义务。敬请广大投资者理性投资，注意投资风险。 证券代码： ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative increase in stock price of over 20% compared to the benchmark index within the next six months [9][14]. Core Views - The company is projected to achieve revenue of 6.383 billion yuan in 2024, representing a year-on-year growth of 35.90%, with a net profit attributable to shareholders of 187 million yuan, up 287.20% year-on-year [3][12]. - The global smartphone market is expected to rebound in 2024, with an estimated shipment of 1.18 billion units, a growth of approximately 6.8% year-on-year, benefiting the company's mobile CIS product segment [3][4]. - The company is enhancing its product structure with a higher proportion of high-pixel CIS products, which is expected to contribute significantly to revenue growth [3][5]. Company Overview - The latest closing price of the company's stock is 15.20 yuan, with a total market capitalization of 39.5 billion yuan [2]. - The company has a total share capital of 2.601 billion shares, with 1.449 billion shares in circulation [2]. - The asset-liability ratio stands at 65.3%, indicating a moderate level of financial leverage [2]. Financial Projections - Revenue projections for the company are as follows: 8.019 billion yuan in 2025, 10.08 billion yuan in 2026, and 13.009 billion yuan in 2027, with respective growth rates of 25.62%, 25.70%, and 29.06% [12][13]. - The net profit attributable to shareholders is expected to reach 303 million yuan in 2025, 703 million yuan in 2026, and 1.303 billion yuan in 2027, with significant growth rates of 62.22%, 132.07%, and 85.30% respectively [12][13]. Business Segments - The company's mobile CIS business is projected to generate revenue of 3.598 billion yuan in 2024, accounting for 56.39% of total revenue, with a year-on-year growth of 60.44% [3][4]. - The non-mobile CIS segment is also expected to grow, with projected revenue of 1.426 billion yuan in 2024, a year-on-year increase of 17.82% [5]. - The display driver chip business is anticipated to achieve revenue of 1.356 billion yuan in 2024, reflecting a growth of 9.47% [8].

Group 1 - BYD reported August sales of 174,915 new energy vehicles, a year-on-year increase of 184.84% [1] - Cumulative sales from January to August reached 978,795 units, representing a year-on-year growth of 267.31% [1] - The company sold 5,092 new energy passenger vehicles overseas in August [1] Group 2 - Zhongke Electric's subsidiary plans to establish a joint venture with Chongqing Fudi for the production of anode materials, with a registered capital of 1 billion RMB [2] - Zhongke Electric's subsidiary will contribute 650 million RMB, while Chongqing Fudi will contribute 350 million RMB [2] Group 3 - Yuyuan Group intends to transfer 13% of its shares in Jinhuijiu for approximately 1.937 billion RMB, reducing its stake to 25% [3] - The company plans to further reduce its holdings by more than 5% within the next six months [3] Group 4 - Lizhu Group's recombinant COVID-19 fusion protein vaccine has been included in the emergency use for sequential booster immunization [4] Group 5 - Guanghui Energy plans to repurchase shares worth between 800 million and 1 billion RMB to support employee stock ownership plans [5] Group 6 - Cambrian has launched four cloud-based intelligent chips, although mass sales will require a longer time frame and initial technical service investments [7] Group 7 - LePu Medical has received approval from the China Securities Regulatory Commission for the issuance of Global Depositary Receipts (GDRs) and listing on the Swiss Stock Exchange [9] - The GDR issuance will correspond to no more than 180,458,875 new A-shares [9] Group 8 - Fushi Holdings' subsidiary has entered into an exclusive advertising agency cooperation with the Central Radio and Television Station's automotive channel for three years [10] Group 9 - Guangzhou Port's container throughput in August was 1.981 million TEUs, a year-on-year increase of 2.4% [11] - The total cargo throughput for August was 44.788 million tons, a decrease of 0.6% [11] Group 10 - Ningbo Port expects to complete a container throughput of 3.58 million TEUs in August, a year-on-year increase of 10.2% [12] - The total cargo throughput is projected to decline by 3.0% [12] Group 11 - Ming Tai Aluminum reported a 7% year-on-year decrease in aluminum plate and strip sales in August, while aluminum profile sales increased by 47% [13] Group 12 - Electric Power Investment plans to invest in multiple wind and solar projects, with total static investments of 1.585 billion RMB for wind and 538 million RMB for solar [14] Group 13 - Northeast Pharmaceutical has signed a cooperation agreement with MedAbome for the development of the MAb11-22.1 antibody project [19] Group 14 - New Five Feng plans to acquire equity in Tianxin Seed Industry and several other companies for a total price of approximately 2.208 billion RMB [26] Group 15 - Sumeida's subsidiary plans to transfer 100% equity of eight photovoltaic power station project companies, with an estimated transaction value of 657 million RMB [27] Group 16 - *ST Tongzhou intends to acquire 51% equity in Tongtaiwei, fulfilling the capital contribution obligation of 10.2 million RMB [29] Group 17 - Tianyin Holdings' subsidiary plans to invest 120 million RMB in Xundong Xintong to acquire 40% equity [30] Group 18 - Hainan Haiyao plans to publicly transfer 43% equity in Shanghai Lishengte to attract new investors [31] Group 19 - New Asia Process plans to transfer 7.76% of its shares to Xiangcai New Materials at a price of 5.274 RMB per share [32] Group 20 - Lanwei Medical plans to raise no more than 664 million RMB through a private placement for provincial laboratory construction projects [34] Group 21 - Lida New Materials plans to issue convertible bonds to raise no more than 300 million RMB for a new aluminum material project [35] Group 22 - Gekewei has successfully launched its 12-inch CIS integrated circuit project, achieving over 95% yield [51] Group 23 - Baijin Medical's tricuspid valve ring product has received registration approval [52] Group 24 - Shanghai Pharmaceuticals has received approval to initiate Phase I clinical trials for a recombinant anti-CD20 humanized monoclonal antibody [53] Group 25 - Junda Co. has increased the production capacity of its solar cell production base project from 8GW to 10GW [54]